Voyager Therapeutics (VYGR) Non-Current Assets (2014 - 2026)
Voyager Therapeutics (VYGR) posted Non-Current Assets of $72.3 million for Q1 2026, up 45.87% sequentially from $49.6 million in Q4 2025, and down 33.04% YoY from $108.0 million in Q1 2025.
Voyager Therapeutics (VYGR) Non-Current Assets (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Non-Current Assets for 13 years, with the latest figure at $72.3 million in Q1 2026.
- Quarterly Non-Current Assets fell 33.04% year-over-year to $72.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $284.9 million (down 14.07% YoY) and the FY2025 annual result came in at $49.6 million, down 57.34% from the prior year.
- Non-Current Assets climbed to $72.3 million in Q1 2026 per VYGR's latest filing, from $49.6 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $116.2 million in Q4 2024 and troughed at $31.6 million in Q4 2023.
- A 5-year average of $57.0 million and a median of $52.6 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets soared 267.89% in 2024, then plunged 57.34% in 2025.
- Over 5 years, Non-Current Assets stood at $34.9 million in 2022, then retreated by 9.35% to $31.6 million in 2023, then jumped by 267.89% to $116.2 million in 2024, then slumped by 57.34% to $49.6 million in 2025, then jumped by 45.87% to $72.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $72.3 million, $49.6 million, and $68.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Voyager Therapeutics | 201.32 Mn | 84.98 Mn | - | 72.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 72.53 Mn |
| Mar 31, 2026 | 72.34 Mn |
| Dec 31, 2025 | 49.59 Mn |
| Sep 30, 2025 | 68.73 Mn |
| Jun 30, 2025 | 94.21 Mn |
| Mar 31, 2025 | 108.03 Mn |
| Dec 31, 2024 | 116.24 Mn |
| Sep 30, 2024 | 52.60 Mn |
| Jun 30, 2024 | 54.66 Mn |
| Mar 31, 2024 | 60.46 Mn |
| Dec 31, 2023 | 31.60 Mn |
| Sep 30, 2023 | 32.73 Mn |
| Jun 30, 2023 | 33.36 Mn |
| Mar 31, 2023 | 33.67 Mn |
| Dec 31, 2022 | 34.86 Mn |
| Sep 30, 2022 | 35.54 Mn |
| Jun 30, 2022 | 36.98 Mn |
| Mar 31, 2022 | 53.53 Mn |
| Dec 31, 2021 | 57.16 Mn |
| Sep 30, 2021 | 58.57 Mn |